Evidence map›Paper›PMID 42016363›Full record

ArticleOpen forum infectious diseases2026

Comparison of Hospitalization Costs Associated With Human Metapneumovirus and Respiratory Syncytial Virus Infection in US Adults.

Bradley K Ackerson, Emily Rayens, Lina S Sy, Hung Fu Tseng, Lei Qian, Yi Luo, Rachelle Juan, Xuan Huang, Jennifer H Ku, Punam P Modha and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bradley K AckersonDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-0816-7345
Emily RayensDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-3369-3475
Lina S SyDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-2762-9266
Hung Fu TsengDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0001-6184-6534
Lei QianDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0001-8001-3992
Yi LuoDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0001-8990-2470
Rachelle JuanDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0009-0002-1222-0011
Xuan HuangDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0009-0001-2161-9123
Jennifer H KuCenter for Integrated Health Care Research, Kaiser Permanente, Honolulu, Hawaii, USA.ORCID https://orcid.org/0000-0001-9469-5875
Punam P ModhaDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0009-0008-2274-1543
Radha M BathalaDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0009-0001-6549-9071
Sudhir VenkatesanBPM Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID https://orcid.org/0000-0002-2093-5781
Lisa GlasserVaccines and Immune Therapies, AstraZeneca, Wilmington, Delaware, USA.ORCID https://orcid.org/0000-0002-9863-7098
Richard McNultyVaccines and Immune Therapies, AstraZeneca, Cambridge, UK.
Daniel MolnarVaccines and Immune Therapies, AstraZeneca, Barcelona, Spain.ORCID https://orcid.org/0000-0002-6785-3812
Chengbin WangVaccines and Immune Therapies, AstraZeneca, Gaithersburg, Maryland, USA.ORCID https://orcid.org/0000-0003-3415-0122
Jaejin AnDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-3161-5732

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hospitalization costs on human metapneumovirus (hMPV) are needed to inform healthcare priorities, including vaccine and treatment development. Among 5775 adult hospitalizations with hMPV or respiratory syncytial virus (RSV), hMPV was associated with shorter length of stay but greater frequency of pneumonia, resulting in adjusted mean costs comparable to RSV hospitalization.

Indexed as

adultcosthospitalizationhuman metapneumovirusrespiratory syncytial virus

Identifiers

PMID42016363
PMCPMC13095376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.